Monday, 18 Feb 2019

You are here

Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis

Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time it’s filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS).


The EQUATOR trial was multicenter, phase 2 study oof 191 patients with active moderate-to-severe PsA. Patients continued their background csDMARDs and were randomized to filgotinib 200 mg or placebo orally once daily. The primary endpoint was the ACR20 response at 16 weeks.

Overall, an ACR20 response was seen in 80% of filgotinib patients but only 33% of the placebo patients (treatment difference 47% [95% CI 30·2–59·6], p<0·0001).

Safety signals were similar. The most common events were nasopharyngitis and headache. 


The TORTUGA trial was a multicenter, phase 2 trial, wherein active AS patients were randomized to receive filgotinib 200 mg or placebo orally daily for 12 weeks. The primary endpoint was the change in the ankylosing spondylitis disease activity score (ASDAS) at week 12. (Citation source:

A total of 116 AS patients were treated. The mean ASDAS change was greater (−1·47) in the filgotinib group compared with placebo (−0·57) treated patients (least squares mean difference between groups of −0·85 (95% CI −1·17 to −0·53; p<0·0001).

There were no deaths reported during the study. Other adverse events were minor and balanced between groups.

These trials suggest that JAK 1 inhibition with filgotinib is efficacious and safe for the treatment ankylosing spondylitis and psoriatic arthritis patients not responding to conventional therapies. 

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Biologics in Psoriasis Tied to Better Heart Health

Biologic therapy for severe psoriasis was associated with better plaque morphology and less non-calcified coronary plaque, according to a prospective, observational study.

Low IBD Risk with Secukinumab

The interleukin-23 (IL-23)/IL-17 axis plays an important role in inflammation and infection. Some of these chronic immune-mediated inflammatory disorders include PsO, PsA, AS, and IBD. Patients with PsO, PsA, and AS have up to a four-fold risk of developing IBD versus the general population. One study also supported the role for gut inflammation in spondyloarthropathy.

Ixekizumab and Complete Resolution of Enthesitis and Dactylitis

IL-17 inhibitors have proven to be effective in psoriatic arthritis. Analyses of ixekizumab-treated PsA patients with enthesitis or dactylitis shows this approach to yield significant improvements in enthesitis and dactylitis.

Obesity Needs to be Treated in Psoriatic Arthritis

Obese patients with psoriatic arthritis (PsA) who followed a short-term, very low-energy diet showed improvements in multiple aspects of disease activity, a prospective study found.

Over a period of 6 months, patients on the restrictive diet (640 kcal/day) lost a median of 18.7 kg (41.2 lbs), which represented 18.6% of their weight, according to Eva Klingberg, MD, PhD, of the University of Gothenburg in Sweden, and colleagues.